Lower fetal fraction in clinical cell‐free DNA screening results is associated with increased risk of hypertensive disorders of pregnancy
Autor: | Deeksha Madala, Mohamad Ali Maktabi, Riwa Sabbagh, Hadi Erfani, Andrea Moon, Ignatia B. Van den Veyver |
---|---|
Rok vydání: | 2022 |
Předmět: | |
Zdroj: | Prenatal Diagnosis. 42:1253-1261 |
ISSN: | 1097-0223 0197-3851 |
DOI: | 10.1002/pd.6221 |
Popis: | To evaluate if fetal fraction (FF) reported on cell-free DNA (cfDNA) screening is a marker for adverse obstetric outcomes.We retrospectively reviewed medical records from a cohort of women with singleton pregnancies who had cfDNA screening. We evaluated if reported FF could predict the following pregnancy complications: hypertensive disorders of pregnancy (HDP), fetal growth restriction, preterm delivery, gestational diabetes mellitus, or a composite maternal morbidity, defined as the presence of at least one of these outcomes.Receiver operating curve analysis was performed on FF from 534 women to define the FF that differentiated a low FF group (10%; N = 259) and a high FF group (≥10%; N = 275). Hypertensive disorders of pregnancy were more common for women in the low FF group (32.0% vs. 11.6% and p 0.001), who had a two-fold odds of developing HDP (p = 0.006). Composite maternal morbidity was also more common for women in the low FF group (51.4% vs. 30.2% and p 0.001), who had a 1.7-fold odds of developing any of the adverse obstetrical outcomes (p = 0.014).We found that low FF on cfDNA screening is associated with an increased risk of HDP. Fetal fraction reported that cfDNA screening reports have potential as a predictive marker for the development of HDP and adverse outcomes. |
Databáze: | OpenAIRE |
Externí odkaz: |